サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1656919

高薬理活性原薬 (HPAPI)：市場洞察・競合情勢・市場予測 (～2032年)

High Potency Active Pharmaceutical Ingredients (HPAPI) - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
高薬理活性原薬 (HPAPI)：市場洞察・競合情勢・市場予測 (～2032年)
出版日: 2025年01月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

高薬理活性原薬 (HPAPI) の市場規模は、2024年の244億362万米ドルから、予測期間中はCAGR 8.00％で推移し、2032年には449億4,439万米ドルの規模に成長すると予測されています。

高薬理活性原薬 (HPAPI) 市場は、主に世界の慢性疾患の罹患率の上昇に後押しされ、力強い成長を遂げています。世界の癌と糖尿病の有病率の増加、API開発と製造に対する政府の支援強化、主要企業による研究開発努力の強化などの要因が、市場拡大を推進する上で極めて重要です。これらの力学は、2025年から2032年までの予測期間を通じて、市場の前向きな成長の勢いを維持すると予想されています。

高薬理活性原薬 (HPAPI) の市場力学：

慢性疾患の増加により、広範な薬物治療が必要となり、革新的な医薬品有効成分 (API) の需要が高まっています。HPAPIは、標的治療用に特別に開発されたもので、より効果的な疾病管理と治療のために患者に個別化された医薬品を提供することを可能にします。世界保健機関 (WHO) が2024年2月に発表したデータによると、2050年までに新たに発生する癌患者は3,500万人を超えると推定され、2022年の推定2,000万人から77％の大幅増となります。2020年に世界で報告された乳癌症例は約226万件、肺癌症例は221万件、大腸癌症例は193万件でした。

国際糖尿病連合 (International Diabetes Federation) が2021年に発表したデータによると、2021年時点で20歳から79歳の成人の約5億3,700万人が糖尿病に罹患しており、この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予想されています。そのため、天然インスリンやメトホルミンなどの抗糖尿病原薬が糖尿病治療に広く使用されており、市場の成長を促進しています。

主要企業による研究開発の発展もHPAPIの成長を促進しています。企業は、高度な研究と技術革新を通じて新規化合物の開発と同定に積極的に取り組んでおり、慢性疾患の治療選択肢の強化に注力しています。

当レポートでは、世界の高薬理活性原薬 (HPAPI) の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 高薬理活性原薬 (HPAPI) 市場レポート：イントロダクション

  • 調査範囲
  • 市場セグメンテーション
  • 市場の前提因子

第2章 高薬理活性原薬 (HPAPI) 市場：エグゼクティブサマリー

  • 市場概要

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 高薬理活性原薬 (HPAPI) 市場：主要要因分析

  • 市場促進要因
    • 慢性疾患の世界的増加
    • 癌と糖尿病の罹患率の世界的増加
    • API開発と製造に対する政府の支援強化
    • 主要企業による研究開発の取り組み
  • 市場抑制要因と課題
    • 高い開発・生産コスト
    • 厳格な品質および規制要件
  • 市場機会
    • 自動化とスマート製造の統合
    • 個別化医療開発への注力

第6章 高薬理活性原薬 (HPAPI) 市場：ポーターのファイブフォース分析

第7章 高薬理活性原薬 (HPAPI) 市場の評価

  • 製造方法別
    • 自然
    • 合成
  • モダリティ別
    • 小分子
    • 生物製剤
    • その他
  • 用途別
    • 腫瘍
    • 神経
    • 心臓病
    • 感染症
    • 代謝性疾患
  • エンドユーザー別
    • バイオ医薬品およびライフサイエンス企業
    • CMO
    • 研究機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 高薬理活性原薬 (HPAPI) 市場：企業・製品プロファイル

  • BASF SE
  • Pfizer Inc.
  • Divi's Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Evonik Industries AG
  • CARBOGEN AMCIS
  • Lonza
  • WuXi AppTec
  • Ajinomoto Bio-Pharma
  • CordenPharma
  • Lupin Limited
  • Piramal Enterprises Ltd.
  • Sanofi
  • Boehringer Ingelheim International GmbH

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: High Potency Active Pharmaceutical Ingredients Market in Global (2022-2032)
  • Table 3: High Potency Active Pharmaceutical Ingredients Market in Global by Production Method (2022-2032)
  • Table 4: High Potency Active Pharmaceutical Ingredients Market in Global by Modality (2022-2032)
  • Table 5: High Potency Active Pharmaceutical Ingredients Market in Global by Application (2022-2032)
  • Table 6: High Potency Active Pharmaceutical Ingredients Market in Global by End-User (2022-2032)
  • Table 7: High Potency Active Pharmaceutical Ingredients Market in Global by Geography (2022-2032)
  • Table 8: High Potency Active Pharmaceutical Ingredients Market in North America (2022-2032)
  • Table 9: High Potency Active Pharmaceutical Ingredients Market in the US (2022-2032)
  • Table 10: High Potency Active Pharmaceutical Ingredients Market in Canada (2022-2032)
  • Table 11: High Potency Active Pharmaceutical Ingredients Market in Mexico (2022-2032)
  • Table 12: High Potency Active Pharmaceutical Ingredients Market in Europe (2022-2032)
  • Table 13: High Potency Active Pharmaceutical Ingredients Market in France (2022-2032)
  • Table 14: High Potency Active Pharmaceutical Ingredients Market in Germany (2022-2032)
  • Table 15: High Potency Active Pharmaceutical Ingredients Market in the United Kingdom (2022-2032)
  • Table 16: High Potency Active Pharmaceutical Ingredients Market in Italy (2022-2032)
  • Table 17: High Potency Active Pharmaceutical Ingredients Market in Spain (2022-2032)
  • Table 18: High Potency Active Pharmaceutical Ingredients Market in Rest of Europe (2022-2032)
  • Table 19: High Potency Active Pharmaceutical Ingredients Market in Asia-Pacific (2022-2032)
  • Table 20: High Potency Active Pharmaceutical Ingredients Market in China (2022-2032)
  • Table 21: High Potency Active Pharmaceutical Ingredients Market in Japan (2022-2032)
  • Table 22: High Potency Active Pharmaceutical Ingredients Market in India (2022-2032)
  • Table 23: High Potency Active Pharmaceutical Ingredients Market in Australia (2022-2032)
  • Table 24: High Potency Active Pharmaceutical Ingredients Market in South Korea (2022-2032)
  • Table 25: High Potency Active Pharmaceutical Ingredients Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: High Potency Active Pharmaceutical Ingredients Market in Rest of the World (2022-2032)
  • Table 27: High Potency Active Pharmaceutical Ingredients Market in the Middle East (2022-2032)
  • Table 28: High Potency Active Pharmaceutical Ingredients Market in Africa (2022-2032)
  • Table 29: High Potency Active Pharmaceutical Ingredients Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: High Potency Active Pharmaceutical Ingredients Market in Global (2022-2032)
  • Figure 3: High Potency Active Pharmaceutical Ingredients Market in Global by Production Method (2022-2032)
  • Figure 4: High Potency Active Pharmaceutical Ingredients Market in Global by Modality (2022-2032)
  • Figure 5: High Potency Active Pharmaceutical Ingredients Market in Global by Application (2022-2032)
  • Figure 6: High Potency Active Pharmaceutical Ingredients Market in Global by End-User (2022-2032)
  • Figure 7: High Potency Active Pharmaceutical Ingredients Market in Global by Geography (2022-2032)
  • Figure 8: High Potency Active Pharmaceutical Ingredients Market in North America (2022-2032)
  • Figure 9: High Potency Active Pharmaceutical Ingredients Market in the US (2022-2032)
  • Figure 10: High Potency Active Pharmaceutical Ingredients Market in Canada (2022-2032)
  • Figure 11: High Potency Active Pharmaceutical Ingredients Market in Mexico (2022-2032)
  • Figure 12: High Potency Active Pharmaceutical Ingredients Market in Europe (2022-2032)
  • Figure 13: High Potency Active Pharmaceutical Ingredients Market in France (2022-2032)
  • Figure 14: High Potency Active Pharmaceutical Ingredients Market in Germany (2022-2032)
  • Figure 15: High Potency Active Pharmaceutical Ingredients Market in the United Kingdom (2022-2032)
  • Figure 16: High Potency Active Pharmaceutical Ingredients Market in Italy (2022-2032)
  • Figure 17: High Potency Active Pharmaceutical Ingredients Market in Spain (2022-2032)
  • Figure 18: High Potency Active Pharmaceutical Ingredients Market in Rest of Europe (2022-2032)
  • Figure 19: High Potency Active Pharmaceutical Ingredients Market in Asia-Pacific (2022-2032)
  • Figure 20: High Potency Active Pharmaceutical Ingredients Market in China (2022-2032)
  • Figure 21: High Potency Active Pharmaceutical Ingredients Market in Japan (2022-2032)
  • Figure 22: High Potency Active Pharmaceutical Ingredients Market in India (2022-2032)
  • Figure 23: High Potency Active Pharmaceutical Ingredients Market in Australia (2022-2032)
  • Figure 24: High Potency Active Pharmaceutical Ingredients Market in South Korea (2022-2032)
  • Figure 25: High Potency Active Pharmaceutical Ingredients Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: High Potency Active Pharmaceutical Ingredients Market in Rest of the World (2022-2032)
  • Figure 27: High Potency Active Pharmaceutical Ingredients Market in the Middle East (2022-2032)
  • Figure 28: High Potency Active Pharmaceutical Ingredients Market in Africa (2022-2032)
  • Figure 29: High Potency Active Pharmaceutical Ingredients Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DISR0207

High Potency Active Pharmaceutical Ingredients (HPAPI) Market By Production Method (Natural and Synthetic), Modality (Small Molecule, Biologics, and Others), Application (Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Diseases, and Others), End-User (Biopharmaceutical and Life Science Companies, Contract Drug Manufacturing Organizations, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of chronic diseases and the increasing prevalence of cancer and diabetes

The high potency active pharmaceutical ingredients (HPAPI) market was valued at USD 24,403.62 million in 2024, growing at a CAGR of 8.00% during the forecast period from 2025 to 2032 to reach USD 44,944.39 million by 2032. The high-potency active pharmaceutical ingredients (HPAPIs) market is experiencing robust growth, primarily fueled by the rising incidence of chronic diseases globally. Factors such as the increasing prevalence of cancer and diabetes worldwide, enhanced governmental support for API development and manufacturing, and heightened research and development efforts by major industry players are pivotal in driving the market's expansion. These dynamics are expected to sustain positive growth momentum for the high-potency active pharmaceutical ingredients market throughout the forecast period from 2025 to 2032.

High Potency Active Pharmaceutical Ingredients Market Dynamics:

The increasing prevalence of chronic diseases necessitates extensive drug treatments, driving the demand for innovative active pharmaceutical ingredients (APIs). High-potency active pharmaceutical ingredients (HPAPIs) are specifically developed for targeted therapies, enabling the provision of personalized medicines to patients for more effective disease management and treatment. For instance, according to data provided by the World Health Organization (WHO) in February 2024, over 35 million new cancer cases were estimated to occur by 2050, marking a significant 77% increase from the estimated 20 million cases in 2022 across the globe. There were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and 1.93 million cases of colon and rectal cancer, reported in the year 2020 in the world.

According to data published by the International Diabetes Federation in 2021, stated that around 537 million adults aged between 20 and 79 years were suffering from diabetes in 2021 in the world and this number is expected to increase from 643 million by 2030 and 783 million by 2045. Therefore, natural insulin and antidiabetic API such as metformin are being widely used for the treatment of diabetes which is fostering market growth.

Greater domestic production of active pharmaceutical ingredients (APIs) can reduce dependency on global supply chains for critical medications, especially during periods of heightened public health demand. Consequently, government organizations are prioritizing efforts to bolster domestic manufacturing capacity for APIs. For instance, in May 2024, the United States Agency for International Development (USAID), unveiled a new initiative called "Diversifying Asia's Pharmaceutical Supply Chain. The project allocated USD 5 million towards the sustainable production, regulation, and export of high-quality medical products and active pharmaceutical ingredients (APIs) in Uzbekistan and Kazakhstan.

The increasing research and development (R&D) efforts by key players are driving the growth of high-potency active pharmaceutical ingredients (APIs). Key companies are actively engaged in developing and identifying novel compounds through advanced research and technological innovations, focusing on enhancing treatment options for chronic diseases. For instance, in May 2024, Lantern Pharma Inc., an artificial intelligence (AI) company specializing in oncology drug discovery and development, revealed a strategic collaboration driven by AI with French biotechnology firm Oregon Therapeutics. The partnership was established to enhance the development of XCE853, a pioneering protein disulfide isomerase (PDI) inhibitor drug candidate, targeting novel and specific cancer indications. Lantern Pharma utilized its proprietary RADR(R) AI platform to identify biomarkers and efficacy-related signatures of XCE853 across various solid tumors, facilitating precision-focused development strategies.

However, the high development and production costs associated with high-potency active pharmaceutical ingredients, and stringent quality and regulatory requirements, among others are some of the key constraints that may limit the growth of the high-potency active pharmaceutical ingredients market.

High Potency Active Pharmaceutical Ingredients Market Segment Analysis:

High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Production Method (Natural and Synthetic), Modality (Small Molecule, Biologics, and Others), Application (Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Diseases, and Others), End-User (Biopharmaceutical and Life Science Companies, Contract Drug Manufacturing Organizations, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the modality segment, the small molecule category was estimated to account for the largest market share in the high-potency active pharmaceutical ingredients market in 2024. This can be attributed to the wide applications of small molecules in drug discovery and development. From traditional small molecules, which have long served as foundations in drug development, to innovative approaches like PROTACs and zirconium cyclosilicates, small molecules designed for oral administration can engage biological targets through diverse modes of action.

Small molecules can act both intracellularly and extracellularly, with their distribution tailored to achieve systemic exposure, potentially including brain penetration capabilities. This versatility highlights the crucial role of small-molecule drugs in advancing therapeutic strategies across diverse medical conditions. For example, data published by the United States Food and Drug Administration (US FDA) in January 2023, revealed that the FDA approved 37 new drugs in 2022, with 21 of them being small molecules, representing 57% of the total. This statistic underscores the continual relevance, impact, and value of small-molecule drugs in driving innovation and progress in pharmaceutical treatments.

In July 2021, Regeneron Pharmaceuticals, Inc., a US-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical and biotechnology company announced a collaboration aimed at researching, developing, and commercializing small molecule compounds targeting the GPR75 receptor. Through this collaboration, Regeneron joined forces with AstraZeneca to develop small molecule compounds that hold potential for treating obesity and related co-morbidities.

Therefore, the wide use of small molecules in drug discovery and development is expected to contribute to the growth of the segment, thereby driving the growth of the high-potency active pharmaceutical ingredients market during the forecast period.

North America is expected to dominate the High Potency Active Pharmaceutical Ingredients Market:

In 2024, North America is projected to lead the high-potency active pharmaceutical ingredients (HPAPIs) market among all regions, driven by a significant patient population affected by chronic diseases like cancer and diabetes. The region's growth is further fueled by the presence of major pharmaceutical companies and increasing governmental support for active pharmaceutical ingredients (API) production. These factors collectively contribute to the expansion of the high-potency active pharmaceutical ingredients market in North America.

According to the National Cancer Institute in 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. The growing number of chronic diseases requires the development of novel active pharmaceutical ingredients for effective treatment, thereby driving market growth.

As per the Centers for Disease Control and Prevention (CDC) in 2021, around 28.7 million people had diabetes in the year 2019 in the United States. Moreover, as per the Centers for Disease Control and Prevention 2022 data, around 96 million people had pre-diabetic conditions in the year 2019 in the US.

Key players in the region are concentrating their efforts on expanding their API production in the United States. For instance, in June 2022, Pfizer Inc. a US-based pharmaceutical and biotechnology company, announced a USD 120 million investment in its Kalamazoo, Michigan facility, emphasizing its commitment to U.S. manufacturing. This investment aims to support the production of its PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) treatment, by expanding the manufacturing capacity for active pharmaceutical ingredients (API) and registered starting materials (RSMs) necessary for nirmatrelvir production. Therefore, the rising activities by key players in the region is expected to propel the growth of North America high potency active pharmaceutical ingredients market.

High Potency Active Pharmaceutical Ingredients Market Key Players:

Some of the key market players operating in the high potency active pharmaceutical ingredients market include BASF SE, Pfizer Inc., Divi's Laboratories Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., Viatris Inc., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Evonik Industries AG, CARBOGEN AMCIS, Lonza, WuXi AppTec, Ajinomoto Bio-Pharma, CordenPharma, Lupin Limited, Piramal Enterprises Ltd., Sanofi, Boehringer Ingelheim International GmbH, and others.

Recent Developmental Activities in the High Potency Active Pharmaceutical Ingredients Market:

  • In July 2023, Evonik Industries AG, a Germany-based chemical and contract manufacturing company announced its collaboration with Heraeus Holding, a Germany-based medical technology and pharmaceutical company for the development of highly potent active pharmaceutical ingredients. The cooperative effort harnesses the specific high-potency active pharmaceutical ingredient (HPAPI) capabilities of both companies, offering a fully integrated solution from the pre-clinical stage through to commercial manufacturing.
  • In June 2022, Merck & Co., Inc., a U.S.-based pharmaceutical company, invested EUR 59 million to establish a contract development and manufacturing facility in Wisconsin, USA. This facility is dedicated to the production of high-potency active pharmaceutical ingredients (HPAPIs) and has effectively doubled Merck's HPAPI production capacity. The expansion aims to meet the growing demand for APIs used in cancer therapies.
  • In March 2022, Lonza, a Switzerland-based pharmaceutical contract manufacturing and development company, announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site in Nansha, China. This expansion specifically enhances the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories. The focus is on supporting the clinical supply of highly potent APIs (HPAPIs), reinforcing Lonza's commitment to advancing pharmaceutical development and production capabilities in the region.
  • In October 2021, Merck & Co., Inc., launched ChetoSensar, an innovative technology to address solubility challenges in ADC and high-potent active pharmaceutical ingredients. This technology underscores Merck's ongoing commitment to investing in innovative modalities and supports the company's objectives to double its capacity for Antibody-Drug Conjugates (ADCs) and high-potency active pharmaceutical ingredients (HPAPIs) in the near future.

Key Takeaways from the High Potency Active Pharmaceutical Ingredients Market Report Study

  • Market size analysis for current High Potency Active Pharmaceutical Ingredients Market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global High Potency Active Pharmaceutical Ingredients market.
  • Various opportunities available for the other competitors in the High Potency Active Pharmaceutical Ingredients Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current High Potency Active Pharmaceutical Ingredients market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for High Potency Active Pharmaceutical Ingredients market growth in the coming future?

Target Audience who can be benefited from this High Potency Active Pharmaceutical Ingredients Market Report Study

  • High Potency Active Pharmaceutical Ingredients product providers
  • Research organizations and consulting companies
  • High Potency Active Pharmaceutical Ingredients related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in High Potency Active Pharmaceutical Ingredients
  • Various end-users who want to know more about the High Potency Active Pharmaceutical Ingredients Market and the latest developments in the High Potency Active Pharmaceutical Ingredients Market.

Frequently Asked Questions for the High Potency Active Pharmaceutical Ingredients Market:

1. What are High Potency Active Pharmaceutical Ingredients?

  • High potency active pharmaceutical ingredients (HPAPIs) are pharmaceutical substances known for their potent therapeutic effects at low doses. They are critical components in the development of medications targeting complex or severe diseases, where precise dosing is essential for effective treatment. Due to their potency, HPAPIs necessitate specialized handling and manufacturing protocols to ensure both worker safety and product purity. They play a pivotal role in the pharmaceutical industry by enabling the creation of advanced therapies tailored to address challenging medical conditions.

2. What is the market for High Potency Active Pharmaceutical Ingredients?

  • The high potency active pharmaceutical ingredients (HPAPI) market was valued at USD 24,403.62 million in 2024, growing at a CAGR of 8.00% during the forecast period from 2025 to 2032 to reach USD 44,944.39 million by 2032.

3. What are the drivers for the global High Potency Active Pharmaceutical Ingredients market?

  • The high potency active pharmaceutical ingredients (HPAPIs) market is experiencing robust growth, primarily fuelled by the rising incidence of chronic diseases globally. Factors such as the increasing prevalence of cancer and diabetes worldwide, enhanced governmental support for API development and manufacturing, and heightened research and development efforts by major industry players are pivotal in driving the market's expansion. These dynamics are expected to sustain positive growth momentum for the high-potency active pharmaceutical ingredients market throughout the forecast period from 2025 to 2032.

4. Who are the key players operating in the global High Potency Active Pharmaceutical Ingredients market?)

  • Some of the key market players operating in the high potency active pharmaceutical ingredients market include BASF SE, Pfizer Inc., Divi's Laboratories Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., Viatris Inc., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Evonik Industries AG, CARBOGEN AMCIS, Lonza, WuXi AppTec, Ajinomoto Bio-Pharma, CordenPharma, Lupin Limited, Piramal Enterprises Ltd., Sanofi, Boehringer Ingelheim International GmbH, and others.

5. Which region has the highest share in the global High Potency Active Pharmaceutical Ingredients market?

  • In 2024, North America is projected to lead the high-potency active pharmaceutical ingredients (HPAPIs) market among all regions, driven by a significant patient population affected by chronic diseases like cancer and diabetes. The region's growth is further fuelled by the presence of major pharmaceutical companies and increasing governmental support for active pharmaceutical ingredients (API) production. These factors collectively contribute to the expansion of the high-potency active pharmaceutical ingredients market in North America.

Table of Contents

1. High Potency Active Pharmaceutical Ingredients Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. High Potency Active Pharmaceutical Ingredients Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. High Potency Active Pharmaceutical Ingredients Market Key Factors Analysis

  • 5.1. High Potency Active Pharmaceutical Ingredients Market Drivers
    • 5.1.1. The rising incidence of chronic diseases globally
    • 5.1.2. The increasing prevalence of cancer and diabetes worldwide
    • 5.1.3. Enhanced governmental support for API development and manufacturing
    • 5.1.4. Research and development efforts by major industry players
  • 5.2. High Potency Active Pharmaceutical Ingredients Market Restraints and Challenges
    • 5.2.1. High development and production cost associated with high potency active pharmaceutical ingredients
    • 5.2.2. Stringent quality and regulatory requirements
  • 5.3. High Potency Active Pharmaceutical Ingredients Market Opportunity
    • 5.3.1. Integration of automation and smart manufacturing
    • 5.3.2. Focus towards personalized medicine development

6. High Potency Active Pharmaceutical Ingredients Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. High Potency Active Pharmaceutical Ingredients Market Assessment

  • 7.1. By Production Method
    • 7.1.1. Natural
    • 7.1.2. Synthetic
  • 7.2. By Modality
    • 7.2.1. Small Molecules
    • 7.2.2. Biologics
    • 7.2.3. Others
  • 7.3. By Application
    • 7.3.1. Oncology
    • 7.3.2. Neurology
    • 7.3.3. Cardiology
    • 7.3.4. Infectious Diseases
    • 7.3.5. Metabolic Diseases
    • 7.3.6. Others
  • 7.4. By End-User
    • 7.4.1. Biopharmaceutical and Life Science Companies
    • 7.4.2. Contract Drug Manufacturing Organizations
    • 7.4.3. Research Institutions
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.3.3. India High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa High Potency Active Pharmaceutical Ingredients Market Size in USD million (2022-2032)
      • 7.5.4.3. South America High Potency Active Pharmaceutical Ingredients Market Size In USD Million (2022-2032)

8. High Potency Active Pharmaceutical Ingredients Market Company and Product Profiles

  • 8.1. BASF SE
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Pfizer Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Divi's Laboratories Limited
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Teva Pharmaceutical Industries Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Eli Lilly and Company
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Merck & Co., Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. AbbVie Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Viatris Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Dr. Reddy's Laboratories Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Sun Pharmaceutical Industries Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Evonik Industries AG
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. CARBOGEN AMCIS
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Lonza
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. WuXi AppTec
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Ajinomoto Bio-Pharma
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. CordenPharma
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Lupin Limited
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Piramal Enterprises Ltd.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Sanofi
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Boehringer Ingelheim International GmbH
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us